Myriad Genetics, Expands Companion Diagnostic Pact with AztraZeneca - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Myriad Genetics, Expands Companion Diagnostic Pact with AztraZeneca



Myriad Genetics, a molecular diagnostics company, has expanded its agreement with AstraZeneca to provide companion diagnostics for olaparib, an anticancer drug candidate. Olaparib is an investigational orally active poly-ADP ribose polymerase (PARP) inhibitor being developed by AstraZeneca treating various tumor types including BRCA-mutated breast and ovarian cancers. BRCA 1 or BRCA 2 gene mutations are responsible for the majority of hereditary breast and ovarian cancers, according to information from Myriad Genetics.

Under the expanded agreement, Myriad will build out a new laboratory within its Salt Lake City, Utah regulations for companion diagnostic devices. In August 2013, FDA approved an investigational device exemption filed by Myriad, for BRCA analysis, a propretiary gentic test by Myriad for identifying patients with BRCA 1 or BRCA 2 gene mutations to enable clinical studies with olaparib to include BRACAnalysis testing as a diagnostic.

The collaboration builds on an existing agreement through which Myriad provided supply of BRACAnalysis to support the Phase II development program for olaparib in breast and ovarian cancers.

Source: Myriad Genetics

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes

Click here